8-K
filed May 7, 2026, 7:59 PM ET
CIK 0000786947
debt
confidence high
sentiment negative
materiality 0.85
Acura's debt to related party grows to $10.3M; warns of possible shutdown without new financing by May-end
ACURA PHARMACEUTICALS, INC
- Received four $100,000 loans from Abuse Deterrent Pharma on March 30, April 3, April 20, May 5, 2026, bringing principal to $10,294,279.
- Accrued interest ~$1,090,000 as of May 5; interest rate 5.25% (7.5% on default).
- Without additional financing by end of May 2026, company will need to scale back operations, furlough employees, or seek bankruptcy.
- AD Pharma, which owns ~65% of Acura's common stock, is controlled by Mr. Schutte, who also owns ~13% directly.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001104659-26-056748
- form_type
- 8-K
- ticker
- null
- cik
- 0000786947
- company_name
- ACURA PHARMACEUTICALS, INC
- filed_at
- 2026-05-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:33.725289+00:00
- generated_at
- 2026-05-14T22:19:21.532855+00:00
- sec_items
- ["1.01", "2.01", "2.03", "9.01"]
- event_type
- debt
- sentiment
- negative
- materiality_score
- 0.85
- calibrated_materiality_score
- 0.85
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001104659-26-056748
- json_url
- https://secwatch.observer/filing/0001104659-26-056748.json
- markdown_url
- https://secwatch.observer/filing/0001104659-26-056748.md
- text_url
- https://secwatch.observer/filing/0001104659-26-056748.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/tm2613771d1_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
TBH
Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger
Brag House Holdings, Inc.
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027
Filing page
SEC filing
KNX
Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver
Knight-Swift Transportation Holdings Inc.
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 8.01, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031
Filing page
SEC filing
PUMP
ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility
ProPetro Holding Corp.
May 7, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 8.01, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031
Filing page
SEC filing
OCGN
Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan
Ocugen, Inc.
May 7, 2026, 7:59 PM ET
debt
Items 1.01, 1.02, 2.02, 2.03, 3.02, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).
Filing page
SEC filing
CORZ
Core Scientific subsidiary prices $3.3B of 7.750% senior secured notes due 2031
Core Scientific, Inc./tx
May 6, 2026, 7:59 PM ET
debt
Items 1.01, 1.02, 2.03, 8.01, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
On May 6, 2026, Core Scientific Finance I LLC (the “Issuer”), a wholly-owned indirect subsidiary of Core Scientific, Inc. (“Core Scientific”), completed its previously announced private offering (the “Offering”) of $3.3 billion aggregate principal amount of its 7.750% Senior Secured Notes due 2031 (the “Notes”).
Filing page
SEC filing
BNZI
Banzai exchanges shares for debt; issued 1.47M shares, note reduced to $819K
Banzai International, Inc.
May 5, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
in the principal amount due under the Note (the “Forbearance Fee”). After giving effect to the Forbearance Fee and the Exchange, the outstanding balance under the Note was $1,839,432.50. The Company also agreed to pay all of Agile’s reasonable costs and expenses, in an amount not to exceed $10,000. Following the initial Exchange, the Company, Agile and the
Filing page
SEC filing
RENX
RenX Enterprises raises up to $100M via tranched convertible note and warrant private placement
RenX Enterprises Corp.
May 5, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 7.01, 8.01, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
Purchase Agreement,
the Company (i) issued and sold to the Purchasers, at the initial closing on May 4, 2026 (the “Initial Closing”), Notes in
the aggregate principal amount of $6,300,000 (the “Initial Notes”) and warrants (the “Initial Warrants”) to purchase
an aggregate of 3,917,099 shares of Common Stock (which is equal to 180% of the face value of the Initial
Filing page
SEC filing
TBCH
Turtle Beach closes $85M term loan and $80M ABL; $56M buyback capacity remains
Turtle Beach Corp
May 4, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 7.01, 9.01
same fact type: debt_financing
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
Comparable filing
a US commitment in an amount equal to $50,000,000 or $65,000,000 based on the season
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.